Forte Biosciences Stock Analysis

FBRX Stock  USD 10.43  0.32  3.17%   
Forte Biosciences is undervalued with Real Value of 19.79 and Target Price of 48.67. The main objective of Forte Biosciences stock analysis is to determine its intrinsic value, which is an estimate of what Forte Biosciences is worth, separate from its market price. There are two main types of Forte Biosciences' stock analysis: fundamental analysis and technical analysis.
The Forte Biosciences stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Forte Biosciences is usually not traded on Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day, Labour Day, Thanksgiving Day, Christmas Day, New Year 's Day. Forte Stock trading window is adjusted to America/New York timezone.
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Forte Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
For more information on how to buy Forte Stock please use our How to Invest in Forte Biosciences guide.

Forte Stock Analysis Notes

About 80.0% of the company shares are owned by institutional investors. The book value of Forte Biosciences was currently reported as 5.84. The company recorded a loss per share of 9.44. Forte Biosciences last dividend was issued on the 16th of June 2020. The entity had 1:25 split on the 28th of August 2024. Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. It is developing FB-102 program that addresses various autoimmune diseases, such as vitiligo and alopecia areata. Forte Biosciences operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 6 people. To learn more about Forte Biosciences call Paul Wagner at 310 618 6994 or check out https://www.fortebiorx.com.

Forte Biosciences Investment Alerts

Forte Biosciences is way too risky over 90 days horizon
Forte Biosciences appears to be risky and price may revert if volatility continues
Net Loss for the year was (35.48 M) with profit before overhead, payroll, taxes, and interest of 0.
Forte Biosciences currently holds about 38.55 M in cash with (30.75 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.89.
Forte Biosciences has a poor financial position based on the latest SEC disclosures
Over 80.0% of the company shares are owned by institutional investors
Latest headline from news.google.com: FBRX SEC Filings - Forte Biosciences Inc 10-K, 10-Q, 8-K Forms - Stock Titan

Forte Biosciences Upcoming and Recent Events

Earnings reports are used by Forte Biosciences to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period..
29th of March 2024
Upcoming Quarterly Report
View
20th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
29th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

Forte Largest EPS Surprises

Earnings surprises can significantly impact Forte Biosciences' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2022-11-14
2022-09-30-0.15-0.18-0.0320 
2023-03-31
2022-12-31-0.16-0.23-0.0743 
2023-05-15
2023-03-31-0.32-0.23220.087827 
View All Earnings Estimates

Forte Biosciences Environmental, Social, and Governance (ESG) Scores

Forte Biosciences' ESG score is a quantitative measure that evaluates Forte Biosciences' performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of Forte Biosciences' operations that may have significant financial implications and affect Forte Biosciences' stock price as well as guide investors towards more socially responsible investments.

Forte Stock Institutional Investors

Shares
Geode Capital Management, Llc2025-03-31
60.1 K
Longwood Capital Partners Llc2025-03-31
18.5 K
Millennium Management Llc2025-03-31
14.6 K
Blackrock Inc2025-03-31
6.8 K
Quest Partners Llc2025-03-31
4.2 K
Garde Capital, Inc.2025-03-31
K
Royal Bank Of Canada2025-03-31
3.3 K
Tower Research Capital Llc2025-03-31
1.8 K
Ubs Group Ag2025-03-31
527
Hhg Plc2025-03-31
920 K
Fred Alger Management, Llc2025-03-31
910.6 K
Note, although Forte Biosciences' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Forte Market Capitalization

The company currently falls under 'Small-Cap' category with a current market capitalization of 123.48 M.

Forte Profitablity

Last ReportedProjected for Next Year
Return On Tangible Assets(0.58)(0.61)
Return On Capital Employed(0.70)(0.73)
Return On Assets(0.58)(0.61)
Return On Equity(0.68)(0.71)

Management Efficiency

Forte Biosciences has return on total asset (ROA) of (0.7065) % which means that it has lost $0.7065 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.3027) %, meaning that it created substantial loss on money invested by shareholders. Forte Biosciences' management efficiency ratios could be used to measure how well Forte Biosciences manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.61 in 2025. Return On Capital Employed is likely to drop to -0.73 in 2025. At this time, Forte Biosciences' Other Current Assets are fairly stable compared to the past year. Debt To Assets is likely to rise to 1.08 in 2025, whereas Total Assets are likely to drop slightly above 43.8 M in 2025.
Last ReportedProjected for Next Year
Book Value Per Share 18.00  17.10 
Tangible Book Value Per Share 18.00  17.10 
Enterprise Value Over EBITDA(1.24)(1.30)
Price Book Value Ratio 1.26  1.20 
Enterprise Value Multiple(1.24)(1.30)
Price Fair Value 1.26  1.20 
Enterprise Value44 M41.8 M
The strategic initiatives led by Forte Biosciences' management are central to its market success. By analyzing these initiatives, we provide a clear picture of the stock's growth prospects.
Beta
2.862
Return On Assets
(0.71)
Return On Equity
(1.30)

Technical Drivers

As of the 22nd of July, Forte Biosciences shows the Coefficient Of Variation of 742.46, downside deviation of 8.24, and Mean Deviation of 6.5. Forte Biosciences technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices.

Forte Biosciences Price Movement Analysis

The output start index for this execution was eight with a total number of output elements of fifty-three. The Simple Moving Average indicator is calculated by adding the closing price of Forte Biosciences for a given number of time periods and then dividing this total by the number of time periods. It is used to smooth out Forte Biosciences short-term fluctuations and highlight longer-term trends or cycles.

Forte Biosciences Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Forte Biosciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Forte Biosciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Forte Biosciences insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Gryska David W over a month ago
Acquisition by Gryska David W of 148514 shares of Forte Biosciences at 1.01 subject to Rule 16b-3
 
Riley Antony A over a month ago
Acquisition by Riley Antony A of 375 shares of Forte Biosciences subject to Rule 16b-3
 
Paul Wagner over three months ago
Acquisition by Paul Wagner of 10520 shares of Forte Biosciences at 0.6988 subject to Rule 16b-3
 
Doberstein Stephen K over three months ago
Acquisition by Doberstein Stephen K of 31000 shares of Forte Biosciences at 7.54 subject to Rule 16b-3
 
Finck Barbara K over three months ago
Acquisition by Finck Barbara K of 31000 shares of Forte Biosciences at 7.02 subject to Rule 16b-3
 
Paul Wagner over three months ago
Acquisition by Paul Wagner of 31250 shares of Forte Biosciences subject to Rule 16b-3
 
Chen Hubert C over three months ago
Acquisition by Chen Hubert C of 7500 shares of Forte Biosciences subject to Rule 16b-3
 
Chen Hubert C over three months ago
Disposition of 2593 shares by Chen Hubert C of Forte Biosciences at 1.01 subject to Rule 16b-3
 
Riley Antony A over six months ago
Disposition of 375 shares by Riley Antony A of Forte Biosciences subject to Rule 16b-3
 
Paul Wagner over six months ago
Disposition of 1250 shares by Paul Wagner of Forte Biosciences subject to Rule 16b-3
 
Paul Wagner over six months ago
Disposition of 11046 shares by Paul Wagner of Forte Biosciences at 1.01 subject to Rule 16b-3
 
Riley Antony A over six months ago
Acquisition by Riley Antony A of 22514 shares of Forte Biosciences at 5.552 subject to Rule 16b-3

Forte Biosciences Outstanding Bonds

Forte Biosciences issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Forte Biosciences uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Forte bonds can be classified according to their maturity, which is the date when Forte Biosciences has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

Forte Biosciences Predictive Daily Indicators

Forte Biosciences intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Forte Biosciences stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Forte Biosciences Corporate Filings

8th of July 2025
Other Reports
ViewVerify
F4
3rd of July 2025
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
8K
25th of June 2025
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
24th of June 2025
Other Reports
ViewVerify
8K
23rd of June 2025
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
8K
30th of May 2025
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
8K
15th of May 2025
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
14th of May 2025
Other Reports
ViewVerify

Forte Biosciences Forecast Models

Forte Biosciences' time-series forecasting models are one of many Forte Biosciences' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Forte Biosciences' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Forte Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Forte Biosciences prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Forte shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Forte Biosciences. By using and applying Forte Stock analysis, traders can create a robust methodology for identifying Forte entry and exit points for their positions.
Last ReportedProjected for Next Year
Pretax Profit Margin(2.36)(2.48)
Operating Profit Margin(2.29)(2.40)
Net Loss(2.44)(2.57)

Current Forte Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Forte analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Forte analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
48.67Strong Buy4Odds
Forte Biosciences current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Forte analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Forte stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Forte Biosciences, talking to its executives and customers, or listening to Forte conference calls.
Forte Analyst Advice Details

Forte Stock Analysis Indicators

Forte Biosciences stock analysis indicators help investors evaluate how Forte Biosciences stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Forte Biosciences shares will generate the highest return on investment. By understating and applying Forte Biosciences stock analysis, traders can identify Forte Biosciences position entry and exit signals to maximize returns.
Begin Period Cash Flow37.1 M
Common Stock Shares Outstanding2.9 M
Total Stockholder Equity52.5 M
Total Cashflows From Investing Activities-36 M
Property Plant And Equipment Net77 K
Cash And Short Term Investments58.4 M
Cash22.2 M
Accounts Payable4.9 M
Net Debt-22.2 M
50 Day M A10.3756
Total Current Liabilities9.1 M
Other Operating Expenses36.6 M
Non Current Assets Total215 K
Non Currrent Assets Other138 K
Stock Based Compensation3.1 M

Additional Tools for Forte Stock Analysis

When running Forte Biosciences' price analysis, check to measure Forte Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Forte Biosciences is operating at the current time. Most of Forte Biosciences' value examination focuses on studying past and present price action to predict the probability of Forte Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Forte Biosciences' price. Additionally, you may evaluate how the addition of Forte Biosciences to your portfolios can decrease your overall portfolio volatility.